Rexahn Pharmaceuticals to Present at the American Society

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

ROCKVILLE, Md., May 23, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that it will present three poster presentations at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, which is being held June 3-7, 2016 in Chicago, Illinois.

The details for the poster presentations at the ASCO Annual Meeting are as follows:

Title:   Results of a Phase 1 Study of RX-5902, An Orally Bioavailable Inhibitor of Phosphorylated p-68 Targeting Solid Tumors Poster #:   Board 254 Abstract #:   2554 Session Date/Time:   Sunday, June 5, 2016 8:00 a.m. – 11:30 a.m. CDT, Hall A Author(s):   Drs. S.G. Eckhardt, W.L. Gluck, M. Gutierrez

Title:   Results of a Phase 1 Study of Single Agent RX-3117, An Oral Antimetabolite Nucleoside to Treat Solid Tumors Poster #:   Board 255 Abstract #:   2555 Session Date/Time:   Sunday, June 5, 2016 8:00 a.m. – 11:30 a.m. CDT, Hall A Author(s):   Dr. D.W. Rasco, and Rexahn Pharmaceuticals

Title:   Results of a Phase 1b/2 Study of RX-0201, A Novel AKT-1 Antisense Combined with Everolimus to Treat Metastatic Clear Cell Renal Carcinoma Poster #:   Board 259 Abstract #:   2559 Session Date/Time:   Sunday, June 5, 2016 8:00 a.m. – 11:30 a.m. CDT Author(s):   Drs. N. Agarwal, S. Tagawa, G. Chatta, S. Pal, S. Goel

Copies of the abstracts are available and can be viewed online through the ASCO website at abstracts.asco.org .  Copies of the poster presentations will be available on Rexahn’s website at www.rexahn.com under the ‘Events and Presentations’ section upon completion of the sessions.

About Rexahn Pharmaceuticals, Inc. Rexahn Pharmaceuticals Inc. (NYSE MKT:RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, best-in-class therapeutics for the treatment of cancer.  The Company’s mission is to improve the lives of cancer patients by developing next generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn’s product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Pre-clinical studies show that certain of Rexahn’s product candidates may be effective against multiple types of cancer, drug resistant cancers, and difficult-to-treat cancers, and others may augment the effectiveness of current FDA-approved cancer treatments.  The Company has a broad oncology pipeline that includes three anti-cancer compounds currently in clinical development: Supinoxin™, RX-3117, and Archexin ® , and a novel nanopolymer-based drug delivery platform technology that may increase the bio-availability of FDA-approved chemotherapies.  For more information about the Company and its oncology programs, please visit  www.rexahn.com .

Safe Harbor To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn’s plans, objectives, expectations and intentions with respect to cash flow requirements, future operations and products, enrollments in clinical trials, the path of clinical trials and development activities, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn’s actual results to be materially different than those expressed in or implied by Rexahn’s forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; that results of preclinical studies and early clinical trials may not be predictive of the results of later-stage clinical trials; the success and design of clinical testing; and Rexahn’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect Rexahn’s actual results are described in Rexahn’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact: Stacey Jurchison Rexahn Investor Relations 240-268-5300 x 324 Jurchisons@rexahn.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Search Is Squeezing Clicks, Not Killing Content Yet

Updated Category News Views 77

A search result that answers the question before earning a click is a nasty little disruption, and marketers are plainly feeling around for solid ground. Goodfirms surveyed 192 content marketing professionals for its 2026 Content Engagement Metrics report, and the headline is more resilient than the prevailing panic: 66.3% said organic website traffic grew over the prior...

Continue Reading
Subaru's 650-Car Anniversary Bet Is Delightfully Small

Updated Category News Views 119

Gold brake calipers may sound like a fussy correction, yet that little detail tells you exactly who Subaru is trying to please. The company has revised its announcement for the 2027 WRX tS GD25 and BRZ tS ZC15, clarifying the anniversary-model names and changing the WRX description from red-painted to gold-painted Brembo calipers. Nobody should confuse a corrected paint...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 172

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
JOYY’s Ad Engine Gives Q3 Growth Some Real Teeth Now

Updated Category News Views 107

Three engines are finally pulling the cart at JOYY, and that is a far more interesting sight than another quarter of livestreaming merely holding together. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% sequentially. Those are sturdy numbers, especially for a business that investors have long tended to box in as...

Continue Reading
J. Harmon Tests a Smarter Cannabis Accessory Niche

Updated Category News Views 53

Aisle Space Is the Real Prize Most cannabis accessory launches arrive dressed up like a gimmick and disappear before anyone has reordered them. J. Harmon has a more sensible target: give women products that look deliberate, work in everyday routines and do not demand designer-level money. The brand is set to debut at MJBizCon 2026 in Las Vegas, with LUVBUDS handling...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 102

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Chainlink, UBS Take $2 Trillion Notes Toward Onchain

Updated Category News Views 9

Paperwork is a lousy moat when a bank can automate the mess. Chainlink and UBS are putting that proposition to work in structured notes, a market with more than $2 trillion in outstanding notional and, frankly, an awful lot of operational clutter. Their production solution uses the Chainlink Runtime Environment, or CRE, to connect UBS systems, smart contracts, market data...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 226

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading
Arbor Realty's Loan Mess Meets a Dividend Shutdown

Updated Category News Views 89

A dividend suspension lands differently when the loan book is already coughing up smoke. Arbor Realty Trust’s latest disclosed numbers are not the sort that investors can shrug off as one ugly quarter and forget by Friday. The company reported a third-quarter 2026 GAAP net loss of $85.4 million, suspended its quarterly cash dividend effective immediately, and described...

Continue Reading
Colon Cleanse Advice Deserves a Careful Read First

Updated Category News Views 23

Wellness copy can sound harmless right up until it blurs comfort guidance with health guidance. HelloNation’s feature on what to expect after a colon cleanse, drawing on Suzanne Childre of Gentle Wellness Center in Santa Monica, lays out a fairly familiar recovery script: drink water, rest, eat lightly, expect some bowel changes, and do not panic over a little fatigue....

Continue Reading

Top 5 Most Recently Viewed Articles

RTX and Cebu Pacific Forge Strategic Engine Maintenance Alliance

Updated Category News Views 201

Strategic Partnership Between RTX and Cebu Pacific In an exciting development for aviation partnerships, Pratt & Whitney, an RTX (NYSE: RTX) business, and Cebu Pacific have entered into a comprehensive long-term agreement aimed at maintaining the efficiency and reliability of Cebu Pacific’s GTF engine fleet. This strategic collaboration underlines the critical role of...

Continue Reading
Hellenic Music Ensemble Embarks on North American Tour

Updated Category News Views 172

The Hellenic Music Ensemble's Exciting North American Tour The Hellenic Music Ensemble is set to take North American audiences on a mesmerizing journey through Greece's rich musical heritage in 2026. Led by the talented Natassa Bofiliou and Giannis Haroulis, alongside special guest star Judy Kuhn, this tour promises to be a landmark event. Celebrating Greek Composers This...

Continue Reading
University of Maryland's Groundbreaking Fundraising Initiative

Updated Category News Views 258

University of Maryland Launches Its Largest Fundraising Campaign The University of Maryland proudly announces its most ambitious fundraising endeavor to date, aimed at elevating education and research. Titled Forward: The University of Maryland Campaign for the Fearless, this initiative seeks to raise an impressive $2.5 billion. With the goal of advancing the university's...

Continue Reading
New Insights on Dowlais Group Plc's Recent Activity

Updated Category News Views 203

Understanding Recent Trading Disclosures by Dowlais Group Plc As the financial landscape continuously evolves, public disclosures play a crucial role in ensuring transparency, trust, and regulatory compliance. Dowlais Group Plc, a notable player in the market, recently had transaction disclosures that are vital for investors and stakeholders alike. The company's exemplary...

Continue Reading
Stock Market Updates: Gains, Losses, and Oil Inventory Trends

Updated Category News Views 142

Recent U.S. Stock Market Movements As the trading day nears its end, U.S. stock indices show promising trends, with the S&P 500 making notable gains recently. This uptrend reflects a resilient market which continues to respond positively amidst economic fluctuations. Key Market Index Performances On Thursday, the Dow Jones Industrial Average climbed by 0.24%, reaching...

Continue Reading